In Vitro and In Vivo Modulation of Alternative Splicing by the Biguanide Metformin

[1]  Paul Theodor Pyl,et al.  HTSeq—a Python framework to work with high-throughput sequencing data , 2014, bioRxiv.

[2]  Anirvan Ghosh,et al.  SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy , 2014, Science.

[3]  J. Valcárcel,et al.  Regulation of FAS exon definition and apoptosis by the Ewing sarcoma protein. , 2014, Cell reports.

[4]  Björn Usadel,et al.  Trimmomatic: a flexible trimmer for Illumina sequence data , 2014, Bioinform..

[5]  L. Tranchevent,et al.  Endothelial, epithelial, and fibroblast cells exhibit specific splicing programs independently of their tissue of origin , 2014, Genome research.

[6]  M. Peschanski,et al.  A defective Krab-domain zinc-finger transcription factor contributes to altered myogenesis in myotonic dystrophy type 1. , 2013, Human molecular genetics.

[7]  M. Cline,et al.  Splicing biomarkers of disease severity in myotonic dystrophy , 2013, Annals of neurology.

[8]  M. Nakamori,et al.  Reducing levels of toxic RNA with small molecules. , 2013, ACS chemical biology.

[9]  Travis L. Rodkey,et al.  Another Surprise from Metformin: Novel Mechanism of Action via K-Ras Influences Endometrial Cancer Response to Therapy , 2013, Molecular Cancer Therapeutics.

[10]  I. Nishino,et al.  Manumycin A corrects aberrant splicing of Clcn1 in myotonic dystrophy type 1 (DM1) mice , 2013, Scientific Reports.

[11]  Y. Chrétien,et al.  Mitogenic insulin receptor-A is overexpressed in human hepatocellular carcinoma due to EGFR-mediated dysregulation of RNA splicing factors. , 2013, Cancer research.

[12]  Brendan J. Quinn,et al.  Inhibition of Lung Tumorigenesis by Metformin Is Associated with Decreased Plasma IGF-I and Diminished Receptor Tyrosine Kinase Signaling , 2013, Cancer Prevention Research.

[13]  O. Mühlemann,et al.  Paraquat Modulates Alternative Pre-mRNA Splicing by Modifying the Intracellular Distribution of SRPK2 , 2013, PloS one.

[14]  R. Scharfmann,et al.  mTOR-dependent proliferation defect in human ES-derived neural stem cells affected by myotonic dystrophy type 1 , 2013, Journal of Cell Science.

[15]  B. Wentworth,et al.  Systemic delivery of a Peptide-linked morpholino oligonucleotide neutralizes mutant RNA toxicity in a mouse model of myotonic dystrophy. , 2013, Nucleic acid therapeutics.

[16]  Cole Trapnell,et al.  TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions , 2013, Genome Biology.

[17]  E. Hoffman,et al.  Metabolic remodeling agents show beneficial effects in the dystrophin-deficient mdx mouse model , 2012, Skeletal Muscle.

[18]  Bruce M. Wentworth,et al.  Targeting nuclear RNA for in vivo correction of myotonic dystrophy , 2012, Nature.

[19]  Masahiro Morita,et al.  Distinct perturbation of the translatome by the antidiabetic drug metformin , 2012, Proceedings of the National Academy of Sciences.

[20]  C. Burge,et al.  The cardiotonic steroid digitoxin regulates alternative splicing through depletion of the splicing factors SRSF3 and TRA2B. , 2012, RNA.

[21]  Chris Williams,et al.  RNA-SeQC: RNA-seq metrics for quality control and process optimization , 2012, Bioinform..

[22]  Marie-France Sagot,et al.  Theme: Computational Biology and Bioinformatics Computational Sciences for Biology, Medicine and the Environment , 2012 .

[23]  G. Dorn,et al.  Bax regulates primary necrosis through mitochondrial dynamics , 2012, Proceedings of the National Academy of Sciences.

[24]  A. Krainer,et al.  THE SPLICING FACTOR SRSF1 REGULATES APOPTOSIS AND PROLIFERATION TO PROMOTE MAMMARY EPITHELIAL CELL TRANSFORMATION , 2011, Nature Structural &Molecular Biology.

[25]  Jeffrey L. Wrana,et al.  An Alternative Splicing Switch Regulates Embryonic Stem Cell Pluripotency and Reprogramming , 2011, Cell.

[26]  Wolfgang Wurst,et al.  Expression of the splicing factor gene SFRS10 is reduced in human obesity and contributes to enhanced lipogenesis. , 2011, Cell metabolism.

[27]  A. Laquérriere,et al.  Misregulated alternative splicing of BIN1 is associated with T tubule alterations and muscle weakness in myotonic dystrophy , 2011, Nature Medicine.

[28]  M. Peschanski,et al.  Mutant human embryonic stem cells reveal neurite and synapse formation defects in type 1 myotonic dystrophy. , 2011, Cell stem cell.

[29]  L. Corcos,et al.  Cotranscriptional exon skipping in the genotoxic stress response , 2010, Nature Structural &Molecular Biology.

[30]  G. Ast,et al.  Alternative splicing and evolution: diversification, exon definition and function , 2010, Nature Reviews Genetics.

[31]  W. Huber,et al.  which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. MAnorm: a robust model for quantitative comparison of ChIP-Seq data sets , 2011 .

[32]  Tyson A. Clark,et al.  Aberrant alternative splicing and extracellular matrix gene expression in mouse models of myotonic dystrophy , 2010, Nature Structural &Molecular Biology.

[33]  G. Dreyfuss,et al.  Rapid-Response Splicing Reporter Screens Identify Differential Regulators of Constitutive and Alternative Splicing , 2010, Molecular and Cellular Biology.

[34]  M. Nakamori,et al.  Pentamidine reverses the splicing defects associated with myotonic dystrophy , 2009, Proceedings of the National Academy of Sciences.

[35]  N. Nukina,et al.  MBNL and CELF proteins regulate alternative splicing of the skeletal muscle chloride channel CLCN1 , 2009, Nucleic acids research.

[36]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[37]  Lili Wan,et al.  RNA and Disease , 2009, Cell.

[38]  D. Black,et al.  A high-throughput screening strategy identifies cardiotonic steroids as alternative splicing modulators , 2008, Proceedings of the National Academy of Sciences.

[39]  Guey-Shin Wang,et al.  Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation. , 2007, Molecular cell.

[40]  J. Tazi,et al.  Inhibition of nonsense-mediated mRNA decay (NMD) by a new chemical molecule reveals the dynamic of NMD factors in P-bodies , 2007, The Journal of cell biology.

[41]  G. Butler-Browne,et al.  Defective mRNA in myotonic dystrophy accumulates at the periphery of nuclear splicing speckles , 2007 .

[42]  S. Sakoda,et al.  Altered mRNA splicing of dystrophin in type 1 myotonic dystrophy , 2007, Muscle & nerve.

[43]  P. Bénit,et al.  Three spectrophotometric assays for the measurement of the five respiratory chain complexes in minuscule biological samples. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[44]  P. Devroey,et al.  Derivation of human embryonic stem cell lines from embryos obtained after IVF and after PGD for monogenic disorders. , 2006, Human reproduction.

[45]  T. Kouki,et al.  Low‐dose metformin improves hyperglycaemia related to myotonic dystrophy , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[46]  T. Cooper,et al.  Muscleblind proteins regulate alternative splicing , 2004, The EMBO journal.

[47]  W. Hauswirth,et al.  A Muscleblind Knockout Model for Myotonic Dystrophy , 2003, Science.

[48]  S. Cannon,et al.  Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. , 2002, Molecular cell.

[49]  T. Cooper,et al.  Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing. , 2002, Molecular cell.

[50]  Margaret S. Wu,et al.  Role of AMP-activated protein kinase in mechanism of metformin action. , 2001, The Journal of clinical investigation.

[51]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[52]  B. Byrne,et al.  Recruitment of human muscleblind proteins to (CUG)n expansions associated with myotonic dystrophy , 2000, The EMBO journal.

[53]  M. Rigoulet,et al.  Dimethylbiguanide Inhibits Cell Respiration via an Indirect Effect Targeted on the Respiratory Chain Complex I* , 2000, The Journal of Biological Chemistry.

[54]  T. Cooper,et al.  Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy. , 1998, Science.

[55]  A. Chinnaiyan,et al.  FADD/MORT1 Is a Common Mediator of CD95 (Fas/APO-1) and Tumor Necrosis Factor Receptor-induced Apoptosis (*) , 1996, The Journal of Biological Chemistry.

[56]  J. Mountz,et al.  Differential expression of human Fas mRNA species upon peripheral blood mononuclear cell activation. , 1995, The Biochemical journal.

[57]  G. Fiucci,et al.  Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. , 1995, Journal of immunology.

[58]  T. Bourgeron,et al.  Biochemical and molecular investigations in respiratory chain deficiencies. , 1994, Clinica chimica acta; international journal of clinical chemistry.

[59]  Matthew J. Brauer,et al.  Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. , 1994, Science.

[60]  C. Amemiya,et al.  Myotonic dystrophy mutation: an unstable CTG repeat in the 3' untranslated region of the gene. , 1992, Science.

[61]  T. Ashizawa,et al.  An unstable triplet repeat in a gene related to myotonic muscular dystrophy. , 1992, Science.

[62]  David E. Housman,et al.  Molecular basis of myotonic dystrophy: Expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member , 1992, Cell.